Literature DB >> 1326671

Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes.

N L Hubbert1, S A Sedman, J T Schiller.   

Abstract

The E6 proteins of the high-risk human papillomaviruses (HPVs) have been shown to form a complex with and induce the degradation of human p53 in vitro. To determine whether p53 is degraded more rapidly in cells expressing E6 in vivo, the half-life of p53 was determined by pulse-chase analysis in early-passage normal human keratinocytes and fibroblasts, human keratinocytes immortalized with HPV type 16 (HPV16) E6 plus E7, and nonimmortal keratinocytes transfected with E6. The results of these experiments indicate that (i) the half-life of newly synthesized p53 is relatively long (4 h) in early-passage human keratinocytes and fibroblasts but short in keratinocytes expressing E6 (15 to 30 min), (ii) a similar increased rate of p53 degradation was measured in lines immortalized with HPV16 E6 plus E7 and senescent cells expressing E6, indicating that this increase is not simply the result of selection in the immortalized lines, and (iii) very low levels of expression of E6 result in a greatly decreased half-life of p53, suggesting that E6 acts in a catalytic manner.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1326671      PMCID: PMC283680     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  The p53 proto-oncogene can act as a suppressor of transformation.

Authors:  C A Finlay; P W Hinds; A J Levine
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

2.  Stability of p53 protein in rat cells transformed by various viral transforming genes.

Authors:  H Inoue; G Kondoh; T M Sudiro; A Hakura
Journal:  Virology       Date:  1992-03       Impact factor: 3.616

3.  Chromosomal integration sites of human papillomavirus DNA in three cervical cancer cell lines mapped by in situ hybridization.

Authors:  A Mincheva; L Gissmann; H zur Hausen
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

4.  The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes.

Authors:  K Münger; W C Phelps; V Bubb; P M Howley; R Schlegel
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

5.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

6.  Association of human papillomavirus types 16 and 18 E6 proteins with p53.

Authors:  B A Werness; A J Levine; P M Howley
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

7.  Suppression of human colorectal carcinoma cell growth by wild-type p53.

Authors:  S J Baker; S Markowitz; E R Fearon; J K Willson; B Vogelstein
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

8.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; J Lukás; A Rejthar; J Kovarík; C A Midgley; J V Gannon; D P Lane
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

9.  Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells.

Authors:  V Band; J A De Caprio; L Delmolino; V Kulesa; R Sager
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

Review 10.  Epidermal differentiation: the bare essentials.

Authors:  E Fuchs
Journal:  J Cell Biol       Date:  1990-12       Impact factor: 10.539

View more
  38 in total

1.  The p53-Mdm2 association in epithelial cells in idiopathic pulmonary fibrosis and non-specific interstitial pneumonia.

Authors:  N Nakashima; K Kuwano; T Maeyama; N Hagimoto; M Yoshimi; N Hamada; M Yamada; Y Nakanishi
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

2.  E2 proteins from high- and low-risk human papillomavirus types differ in their ability to bind p53 and induce apoptotic cell death.

Authors:  Joanna L Parish; Anna Kowalczyk; Hsin-Tien Chen; Geraldine E Roeder; Richard Sessions; Malcolm Buckle; Kevin Gaston
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes.

Authors:  L M Alvarez-Salas; A E Cullinan; A Siwkowski; A Hampel; J A DiPaolo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

4.  Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16.

Authors:  L Sherman; R Schlegel
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Adeno-associated virus type 2 increases proteosome-dependent degradation of p21WAF1 in a human papillomavirus type 31b-positive cervical carcinoma line.

Authors:  Samina Alam; Ellora Sen; Heidi Brashear; Craig Meyers
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

6.  Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins.

Authors:  R M Melillo; K Helin; D R Lowy; J T Schiller
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

7.  HPV and p53 in cervical cancer.

Authors:  H Y Ngan; M Stanley; S S Liu; H K Ma
Journal:  Genitourin Med       Date:  1994-06

Review 8.  Viruses associated with human cancer.

Authors:  Margaret E McLaughlin-Drubin; Karl Munger
Journal:  Biochim Biophys Acta       Date:  2007-12-23

9.  Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53.

Authors:  M Scheffner; J M Huibregtse; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

Review 10.  HPV-p53-miR-34a axis in HPV-associated cancers.

Authors:  Jiezhong Chen; Kong-Nan Zhao
Journal:  Ann Transl Med       Date:  2015-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.